CNHC Quote, Financials, Valuation and Earnings

Kaanapali Land LLC has a net margin of -106.67% compared to China Health Management Corp.'s net margin of -115.2%. China Health Management Corp.'s return on equity of -- beat Kaanapali Land LLC's return on equity of -4.73%.

China Health Management Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kaanapali Land LLC has an analysts' consensus of -- which suggests that it could fall by --. Given that China Health Management Corp. has higher upside potential than Kaanapali Land LLC, analysts believe China Health Management Corp. is more attractive than Kaanapali Land LLC.

China Health Management Corp. has a beta of -1.613, which suggesting that the stock is 261.347% less volatile than S&P 500. In comparison Kaanapali Land LLC has a beta of 0.107, suggesting its less volatile than the S&P 500 by 89.326%.

China Health Management Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kaanapali Land LLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Health Management Corp. pays -- of its earnings as a dividend. Kaanapali Land LLC pays out -- of its earnings as a dividend.

China Health Management Corp. quarterly revenues are $13.5K, which are smaller than Kaanapali Land LLC quarterly revenues of $467K. China Health Management Corp.'s net income of -$14.4K is higher than Kaanapali Land LLC's net income of -$538K. Notably, China Health Management Corp.'s price-to-earnings ratio is 30.00x while Kaanapali Land LLC's PE ratio is 94.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Health Management Corp. is 4.73x versus 26.94x for Kaanapali Land LLC. Usually stocks with elevated PS ratios are considered overvalued.

Marcus & Millichap, Inc. has a net margin of -106.67% compared to China Health Management Corp.'s net margin of 5.46%. China Health Management Corp.'s return on equity of -- beat Marcus & Millichap, Inc.'s return on equity of -0.31%.

China Health Management Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Marcus & Millichap, Inc. has an analysts' consensus of $28.00 which suggests that it could grow by 8.7%. Given that Marcus & Millichap, Inc. has higher upside potential than China Health Management Corp., analysts believe Marcus & Millichap, Inc. is more attractive than China Health Management Corp..

China Health Management Corp. has a beta of -1.613, which suggesting that the stock is 261.347% less volatile than S&P 500. In comparison Marcus & Millichap, Inc. has a beta of 1.325, suggesting its more volatile than the S&P 500 by 32.499%.

China Health Management Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marcus & Millichap, Inc. offers a yield of 1.94% to investors and pays a quarterly dividend of $0.25 per share. China Health Management Corp. pays -- of its earnings as a dividend. Marcus & Millichap, Inc. pays out 163.61% of its earnings as a dividend.

China Health Management Corp. quarterly revenues are $13.5K, which are smaller than Marcus & Millichap, Inc. quarterly revenues of $244M. China Health Management Corp.'s net income of -$14.4K is lower than Marcus & Millichap, Inc.'s net income of $13.3M. Notably, China Health Management Corp.'s price-to-earnings ratio is 30.00x while Marcus & Millichap, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Health Management Corp. is 4.73x versus 1.33x for Marcus & Millichap, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Newmark Group, Inc. has a net margin of -106.67% compared to China Health Management Corp.'s net margin of 6.45%. China Health Management Corp.'s return on equity of -- beat Newmark Group, Inc.'s return on equity of 8.78%.

China Health Management Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Newmark Group, Inc. has an analysts' consensus of $21.00 which suggests that it could grow by 39.07%. Given that Newmark Group, Inc. has higher upside potential than China Health Management Corp., analysts believe Newmark Group, Inc. is more attractive than China Health Management Corp..

China Health Management Corp. has a beta of -1.613, which suggesting that the stock is 261.347% less volatile than S&P 500. In comparison Newmark Group, Inc. has a beta of 1.915, suggesting its more volatile than the S&P 500 by 91.507%.

China Health Management Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Newmark Group, Inc. offers a yield of 0.8% to investors and pays a quarterly dividend of $0.03 per share. China Health Management Corp. pays -- of its earnings as a dividend. Newmark Group, Inc. pays out 34.82% of its earnings as a dividend. Newmark Group, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

China Health Management Corp. quarterly revenues are $13.5K, which are smaller than Newmark Group, Inc. quarterly revenues of $906.8M. China Health Management Corp.'s net income of -$14.4K is lower than Newmark Group, Inc.'s net income of $58.5M. Notably, China Health Management Corp.'s price-to-earnings ratio is 30.00x while Newmark Group, Inc.'s PE ratio is 26.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Health Management Corp. is 4.73x versus 1.11x for Newmark Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Real Brokerage, Inc. has a net margin of -106.67% compared to China Health Management Corp.'s net margin of -0.05%. China Health Management Corp.'s return on equity of -- beat The Real Brokerage, Inc.'s return on equity of -26.76%.

China Health Management Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand The Real Brokerage, Inc. has an analysts' consensus of $5.93 which suggests that it could grow by 125.29%. Given that The Real Brokerage, Inc. has higher upside potential than China Health Management Corp., analysts believe The Real Brokerage, Inc. is more attractive than China Health Management Corp..

China Health Management Corp. has a beta of -1.613, which suggesting that the stock is 261.347% less volatile than S&P 500. In comparison The Real Brokerage, Inc. has a beta of 1.040, suggesting its more volatile than the S&P 500 by 3.982%.

China Health Management Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Real Brokerage, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Health Management Corp. pays -- of its earnings as a dividend. The Real Brokerage, Inc. pays out -- of its earnings as a dividend.

China Health Management Corp. quarterly revenues are $13.5K, which are smaller than The Real Brokerage, Inc. quarterly revenues of $568.5M. China Health Management Corp.'s net income of -$14.4K is higher than The Real Brokerage, Inc.'s net income of -$280K. Notably, China Health Management Corp.'s price-to-earnings ratio is 30.00x while The Real Brokerage, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Health Management Corp. is 4.73x versus 0.31x for The Real Brokerage, Inc.. Usually stocks with elevated PS ratios are considered overvalued.